Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0000950170-24-134524
Filing Date
2024-12-09
Accepted
2024-12-09 16:10:04
Documents
1
Period of Report
2024-10-30

Document Format Files

Seq Description Document Type Size
1 4 ownership.html 4  
1 4 ownership.xml 4 5718
  Complete submission text file 0000950170-24-134524.txt   7275
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Issuer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O MINK THERAPEUTICS 149 FIFTH AVENUE NEW YORK NY 10010
Business Address
Kadlec Robert Peter (Reporting) CIK: 0002047073 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40908 | Film No.: 241535195